Clinical trial
Phase II Clinical Trial, Non-Randomized, Multicentre, on the Combination of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)
NCT00496301 is registered in ClinicalTrials.gov with Spanish Oncology Genito-Urinary Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Clinical Trial, Non-Randomized, Multicentre, on the Combination of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)
- Lead sponsor
- Spanish Oncology Genito-Urinary Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- December 31, 2008
- Enrollment
- 40 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.